Table 1.
Clinical Characteristics of 34 Patients with PT-DLBCL
| Characteristics | group | n (%) |
|---|---|---|
| Age | ||
| ≤60 | 10(29.4%) | |
| >60 | 24(70.6%) | |
| Testicular lymphoma involvement | ||
| Unilateral | 28(82.4%) | |
| Bilateral | 6(17.6%) | |
| Tumor size (cm) | ||
| < 7.5 | 24(70.6%) | |
| ≥ 7.5 | 10(29.4%) | |
| LDH | ||
| Normal | 24(70.6%) | |
| Abnormal | 10(29.4%) | |
| IPI | ||
| 0-1 | 19(55.9%) | |
| 2 | 10(29.4%) | |
| 3 | 5(14.7%) | |
| Ki-67(%) | ||
| <90 | 14(41.2%) | |
| ≥90 | 20(58.8%) | |
| Intrathecal prophylaxis | ||
| Yes | 24(70.6%) | |
| No | 9(26.5%) | |
| Missing | 1(2.9%) | |
| Chemotherapy regimen | ||
| CHOP (like) | 5(14.7%) | |
| R+CHOP (like) | 29(85.3%) |
Abbreviations: LDH, Lactate dehydrogenase; IPI, International Prognostic Index; CHOP, cyclophosphamide, doxorubicin, vincristine, and prednisone; R, rituximab.